Type 1 Diabetes (T1D) | SNP Array
Discrimination between T1D and other non-autoimmune Diabetes
- Whole Blood Sample
- Accurate discrimination between T1D and other non-autoimmune Diabetes, preventing misdiagnosis.
- Results available in less than 3 hours.
- Can aid accurate diagnosis to ensure proper patient care management and prevention of life-threatening complications.
- Provides rapid genetic risk assessment for T1D.
- Ability to genotype 10 SNPs associated with T1D.
ADDRESSING DIABETES MISDIAGNOSIS
Type 1 Diabetes (T1D) is largely genetic and is associated with over 50 genetic signatures, many of which are single nucleotide polymorphisms (SNPs), whereas Type 2 Diabetes (T2D) typically involves insulin resistance often influenced by lifestyle factors
With common misdiagnosis of Type 1 or Type 2 Diabetes, it is estimated that up to of half people with diabetes receive the wrong treatment, this often results in unnecessary initial insulin therapy, higher drug and monitoring costs. Incorrect classification of T1D as T2D can result in poor glycaemic control, frequent healthcare visits, inappropriate insulin regimes and risk of Diabetic Ketoacidosis.
A SIMPLE SOLUTION FOR CORRECT DIAGNOSIS OF TYPE 1 DIABETES
Using patented Biochip array technology, Randox have developed a Type 1 Diabetes (T1D) Genetic Risk Score (GRS) Array in partnership with the University of Exeter. The test involves rapid qualitative genotyping of 10 SNPs from both HLA and non-HLA regions associated with T1D risk. The array can be used to calculate a Genetic Risk Score (GRS), that in combination with other clinical factors can aid in the discrimination of T1D from other non-autoimmune diabetes.
The Randox T1D test provides a simple solution for correct diagnosis, while also assisting with:
- Identification diagnostics: Determining which people with diabetes have a genetic mutation causing it.
- Predictive diagnostics: Determining whether a person will develop diabetes in the future.
SNP Targets Detected
KEY FEATURES
- Genetic Risk Score (GRS): The biochip utilises a Genetic Risk Score . This score helps classify diabetes types and predict future Type 1 Diabetes by analysing specific genetic markers.
- Accurate Diagnosis: By distinguishing between Type 1 and Type 2 Diabetes, the biochip aids in accurate diagnosis, ensuring appropriate treatment and management for patients.
- Early Detection: The biochip’s ability to identify individuals at high risk of developing Type 1 Diabetes allows for timely intervention, potentially delaying or preventing the onset of the disease.
IMPACT ON TREATMENT
Early identification of high-risk individuals through the T1D biochip allows for timely intervention using newly developed drugs, improving clinical outcomes and potentially delaying or preventing the onset of Type 1 Diabetes. By detecting genetic markers associated with T1D, healthcare providers can monitor these individuals more closely and implement preventive measures sooner.
This early and accurate diagnosis ensures that patients receive the most appropriate treatment from the outset, leading to better glycaemic control, reduced complications, and overall improved quality of life. The genetic insights provided by the T1D biochip enable personalised treatment plans, enhancing the effectiveness of interventions and supporting long-term health management. Additionally, the proactive approach supported by the T1D biochip can reduce the burden on healthcare systems and contribute to ongoing research in diabetes, leading to the development of new therapies and preventive strategies.
Meet the Evidence Investigator
Renowned for its versatility, robustness and effective reporting methods, the Evidence Investigator is a semi-automated, benchtop platform that offers efficient and comprehensive testing without compromising accuracy.
Using chemiluminescent as a measurement principle, the Evidence Investigator consistently delivers accurate results.
All data is analysed on-board, removing issues related to human error and result manipulation.
Meet the Biochip
Biochip Technology from Randox utilises multiplex testing methodology in a rapid, accurate and easy-to-use format, catering both molecular and immunoassay testing.
Each biochip can have up to 49 Discrete Test Regions (DTR), meaning that 44 tests can be carried out simultaneously.
Using protein and DNA based biochips provides the user the ability to consolidate tests.
